Emergent BioSolutions, Inc. acquires Trubion Pharmaceuticals

Emergent BioSolutions, Inc., of Rockville, Maryland, recently announced that it had completed the acquisition of Trubion Pharmaceuticals, Inc.

Trubian Pharmaceuticals approved the merger with a majority vote at a special meeting conducted at its Seattle headquarters.

The merger is intended to provide Emergent BioSolutions, Inc., with multiple advanced stage candidates in the areas of oncology and autoimmunity. It will also give the Rockville-based company access to novel and flexible protein therapeutic platforms.

Trubion’s platforms have been formulated to take on the limitations of monoclonal antibodies that complement the company’s existing antibody therapeutic capabilities.

"Emergent's acquisition of Trubion helps achieve our goal of diversifying beyond infectious diseases and marks an important step towards being a fully integrated biopharmaceutical company," Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, Inc, said. "We look forward to growing our presence in the state's vibrant biotech community building on the strengths of the Emergent Seattle team in the field of biotherapeutics."

Trubion's research facilities will remain in Seattle, with the location now slated to become a therapeutics-focused product development site.

Emergent BioSolutions, Inc., is a global biopharmaceutical company that specializes in the development, manufacture and commercialization of antibody therapies and vaccines.